Michelle Zanette

[¹⁸F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid‐β pathology

Dietmar Rudolf Thal, Thomas G. Beach, Michelle Zanette et al. · Alzheimer s & Dementia · 2015 · 152 citations · Full text

Medicine, Neurology, Pathology +17

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

Miloš D. Ikonomović, Christopher Buckley, Kerstin Heurling et al. · Acta Neuropathologica Communications · 2016 · 101 citations · Full text

Medicine, Neurology, Nuclear Medicine +17

Performance of [¹⁸F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA‐AA recommendations for the neuropathologic diagnosis of Alzheimer's disease

Stephen Salloway, José E. Gámez, Upinder Singh et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2017 · 92 citations · Full text

Medicine, Neurology, Pathology +17

Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment

David A. Wolk, Carl Sadowsky, Beth Safirstein et al. · JAMA Neurology · 2018 · 87 citations · Full text

Medicine, Neurology, Neuroscience +17

Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition

Dietmar Rudolf Thal, Thomas G. Beach, Michelle Zanette et al. · Acta Neuropathologica · 2018 · 52 citations · Full text

Medicine, Neurology, Nuclear Medicine +17